サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786552

てんかん治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Epilepsy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 380 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
てんかん治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年08月06日
発行: Persistence Market Research
ページ情報: 英文 380 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のてんかん治療の市場規模は、2025年に81億2,010万米ドルになるとみられ、2025年～2032年の予測期間に7.7%のCAGRで拡大し、2032年には136億4,810万米ドルに達すると予測されています。

てんかん治療には、発作の制御と患者のQOL向上を目的とした様々な治療オプションが含まれます。これには、抗てんかん薬（AED）、外科的介入、神経刺激装置、食事療法などが含まれます。てんかん治療市場は、病院、専門クリニック、外来診療センター、在宅介護の各分野で、医薬品やデバイスをベースとした幅広いソリューションポートフォリオを提供しています。市場開拓の原動力は、てんかんの世界の有病率の上昇、発作管理に対する意識の高まり、薬剤開発や神経技術における技術革新の進展です。

市場成長の促進要因：

世界のてんかん治療市場は、ヘルスケアアクセスの改善による診断率の上昇、WHOやてんかん財団などの組織による啓発活動など、いくつかの主要な要因によって推進されています。副作用の少ない次世代AEDの開発を含む抗てんかん薬の開発や、レーザーアブレーションや反応性神経刺激などの低侵襲手術技術の採用拡大が、市場の拡大に大きく寄与しています。さらに、ウェアラブル発作モニタリング機器とモバイルヘルスアプリの統合により、患者のアドヒアランスとモニタリングが強化され、臨床転帰が改善されます。

市場の抑制要因：

てんかん治療市場は、その成長性にもかかわらず、AEDの長期使用に伴う副作用や薬剤耐性など、いくつかの課題に直面しています。低所得地域では先進的な治療オプションへのアクセスが限られており、外科手術や神経刺激装置のコストが高いことが、市場浸透の妨げとなっています。さらに、特定の地域ではてんかんに対する社会的烙印や教育不足が診断や治療の障壁となっています。また、機器の承認に関連する規制上のハードルや、長い薬剤開発期間も主な制約となっています。

市場機会

てんかん治療市場は、遠隔医療やデジタルヘルスソリューションの拡大を通じて、特に遠隔地や医療が行き届いていない地域の患者にとって大きな成長機会を提供します。遺伝子治療、個別化医療、疾患修飾治療に焦点を当てた進行中のR&Dは、てんかん治療の展望を一変させる可能性を秘めています。ヘルスケアのインフラが整備されつつある新興国は、特にジェネリックAEDの利用可能性が高まっていることや、政府が資金を提供する医療プログラムによって、未開拓の市場の可能性を秘めています。バイオ医薬品企業と学術機関の戦略的提携は、イノベーションと市場参入を加速させる可能性があります。

当レポートでは、世界のてんかん治療市場について調査し、診断・治療タイプ別、発作タイプ別、流通チャネル別、サービスプロバイダー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 世界のてんかん治療市場-エグゼクティブサマリー

  • 世界市場の見通し
  • 需要側の動向
  • 供給側の動向
  • 分析と推奨事項

第2章 市場概要

第3章 主要な市場動向

第4章 付加価値のある洞察

  • 地域別採用分析
  • 規制シナリオ
  • 地域別保険償還シナリオ（保険適用データ）
  • 国・地域別および主要参入企業別の治療費
  • 国/地域別の診断コスト
  • 国/地域別の年間患者数
  • 各国/地域の主要センターが強調表示されたクリニック数
  • バリューチェーン分析
  • PESTLE分析
  • 主なプロモーション戦略

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
  • 2022年の市場シナリオ

第7章 世界てんかん治療市場の需要（金額：100万米ドル）分析

  • 市場規模の歴史的分析、2019年～2024年
  • 現在および将来の市場規模予測、2025年～2032年

第8章 世界のてんかん治療市場分析、診断・治療タイプ別

  • イントロダクション/主な調査結果
  • 市場規模の推移分析（100万米ドル）、診断・治療タイプ別、2019年～2024年
  • 現在および将来の市場規模分析予測（100万米ドル）、診断・治療タイプ別、2025年～2032年
    • 診断別
      • 入院患者
      • 外来
    • 治療タイプ別
      • 薬物治療
        • ラモトリギン
        • フェニトイン
        • カルバマゼピン
        • バルプロ酸
        • その他
      • 手術治療
      • その他
    • 装置別
      • モニタリング装置
      • 神経刺激装置
  • 市場の魅力分析、診断・治療タイプ別

第9章 世界のてんかん治療市場分析（2019年～2024年）と予測（2025年～2032年）、発作タイプ別

  • イントロダクション/主な調査結果
  • 市場規模の推移分析（100万米ドル）、発作タイプ別、2019年～2024年
  • 現在および将来の市場規模分析予測（100万米ドル）、発作タイプ別、2025年～2032年
    • 全身発作
    • 局所発作
    • 両方
  • 市場の魅力分析、発作タイプ別

第10章 世界市場分析、流通チャネル別

  • イントロダクション/主な調査結果
  • 市場規模の推移分析（100万米ドル）、流通チャネル別、2019年～2024年
  • 現在および将来の市場規模分析予測（100万米ドル）、流通チャネル別、2025年～2032年
    • 病院薬局
    • 小売薬局
    • ドラッグストア
    • オンライン薬局
  • 市場の魅力分析、流通チャネル別

第11章 世界市場分析、サービスプロバイダー別

  • イントロダクション/主な調査結果
  • 市場規模の推移分析（100万米ドル）、サービスプロバイダー別、2019年～2024年
  • 現在および将来の市場規模分析予測（100万米ドル）、サービスプロバイダー別、2025年～2032年
    • 病院
    • 外来手術センター
    • 診断センター
    • 専門クリニック
  • 市場の魅力分析、サービスプロバイダー別

第12章 世界市場分析、地域別

  • イントロダクション
  • 市場規模の推移分析（100万米ドル）、地域別、2019年～2024年
  • 現在および将来の市場規模分析予測（100万米ドル）、地域別、2025年～2032年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別市場の魅力分析

第13章 北米市場分析

第14章 ラテンアメリカ市場分析

第15章 欧州市場分析

第16章 南アジア市場分析

第17章 東アジア市場分析

第18章 オセアニア市場分析

第19章 中東・アフリカ市場分析

第20章 市場構造分析

第21章 競合分析

  • 競合ダッシュボード
  • ブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細
    • Medtronic Plc.
    • GlaxoSmithKline
    • Sun Pharmaceutical Industries Ltd
    • Novartis India Ltd
    • Teva Pharma Ltd
    • Zydus Cadila Healthcare Ltd.
    • Boston Scientific Corporation
    • ElectroCore, Inc.
    • LivaNova PLC
    • NIHON KOHDEN CORPORATION
    • Natus Medical Incorporated
    • Neuro Soft
    • Pfizer Inc.
    • Abbott Laboratories
    • Sanofi SA
    • Cipla Ltd.
    • Torrent Pharmaceuticals Ltd

第22章 前提と使用される頭字語

第23章 調査手法

目次
Product Code: PMRREP33476

Persistence Market Research has recently released a comprehensive report on the worldwide market for epilepsy treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Epilepsy Treatment Market Size (2025E): USD 8,120.1 Million
  • Projected Market Value (2032F): USD 13,648.1 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.7%

Epilepsy Treatment Market - Report Scope:

Epilepsy treatment encompasses a range of therapeutic options aimed at controlling seizures and improving quality of life for patients. These include anti-epileptic drugs (AEDs), surgical interventions, neurostimulation devices, and dietary therapies. The epilepsy treatment market serves hospitals, specialty clinics, ambulatory care centers, and homecare settings, with a wide portfolio of pharmaceutical and device-based solutions. Market growth is driven by the rising global prevalence of epilepsy, increasing awareness about seizure management, and ongoing innovations in drug development and neurotechnology.

Market Growth Drivers:

The global epilepsy treatment market is propelled by several key factors, including increasing diagnosis rates due to improved healthcare access and awareness initiatives by organizations like WHO and epilepsy foundations. Advances in anti-epileptic medications, including the development of next-generation AEDs with fewer side effects, and the growing adoption of minimally invasive surgical techniques such as laser ablation and responsive neurostimulation significantly contribute to market expansion. Furthermore, the integration of wearable seizure monitoring devices and mobile health apps enhances patient adherence and monitoring, thereby improving clinical outcomes.

Market Restraints:

Despite its growth potential, the epilepsy treatment market faces several challenges, such as the side effects and drug resistance associated with long-term AED use. Limited accessibility to advanced treatment options in low-income regions and the high cost of surgical procedures and neurostimulation devices hinder wider market penetration. Additionally, the social stigma and lack of education around epilepsy in certain regions create barriers to diagnosis and treatment. Regulatory hurdles related to device approvals and lengthy drug development timelines also present key constraints.

Market Opportunities:

The epilepsy treatment market offers significant growth opportunities through the expansion of telemedicine and digital health solutions, particularly for patients in remote or underserved areas. Ongoing R\&D focused on gene therapy, personalized medicine, and disease-modifying treatments represents a transformative potential for the epilepsy care landscape. Emerging economies with improving healthcare infrastructure offer untapped market potential, especially with the growing availability of generic AEDs and government-funded health programs. Strategic collaborations between biopharmaceutical companies and academic institutions can accelerate innovation and market access.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the epilepsy treatment market globally?
  • Which treatment modalities and technologies are influencing epilepsy care across healthcare systems?
  • How are recent advancements in neurostimulation and digital health reshaping the epilepsy treatment landscape?
  • Who are the key players in the epilepsy treatment market, and what strategies are they adopting for competitive positioning?
  • What are the emerging trends and future prospects in the global epilepsy treatment market?

Competitive Intelligence and Business Strategy:

These firms are investing heavily in clinical trials, drug repurposing, and device development to expand their product portfolios. Partnerships with hospitals, research centers, and digital health firms are enhancing product delivery and care coordination. Additionally, marketing strategies focused on physician education and community awareness are helping to reduce stigma and boost early treatment adoption.

Key Companies Profiled:

  • Medtronic Plc.
  • GlaxoSmithKline
  • Sun Pharmaceutical Industries Ltd
  • Novartis India Ltd
  • Teva Pharma Ltd
  • Zydus Cadila Healthcare Ltd.
  • Boston Scientific Corporation
  • ElectroCore, Inc.
  • LivaNova PLC
  • NIHON KOHDEN CORPORATION
  • Natus Medical Incorporated
  • Neuro Soft
  • Pfizer Inc.
  • Abbott Laboratories
  • Sanofi S.A.
  • Cipla Ltd.
  • Torrent Pharmaceuticals Ltd

Epilepsy Treatment Market Research Segmentation:

Diagnosis & Treatment Type:

  • Diagnosis
    • * Inpatient
    • * Outpatient
  • Treatment Type
    • * Drugs
    • * Lamotrigine
    • * Phenytoin
    • * Carbamazepine
    • * Valproic Acid
    • * Others
    • * Surgery Treatment
    • * Other Treatments
  • Devices
    • * Monitoring Devices
    • * Electrocorticography (ECoG) Electrodes
    • * Intraoperative Patient Monitoring Devices
    • * Neurostimulation Devices
    • * Responsive Neurostimulation
    • * Deep Brain Stimulation
    • * Vagus Nerve Stimulation

Seizure Type:

  • Generalized Seizures
  • Focal Seizures
  • Both

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Service Provider:

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Specialty Clinics

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Global Epilepsy Treatment Market- Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply-Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion and Exclusion

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Indication Innovation / Development Trends

4. Value Added Insights

  • 4.1. Adoption Analysis, By Region
  • 4.2. Regulatory Scenario
  • 4.3. Reimbursement Scenario (Data on Insurance Coverage) By Region
  • 4.4. Cost of Treatment by Country/Region and Key Players
  • 4.5. Costs of Diagnosis by Country/Region.
  • 4.6. Annual Patient Volume by Country/Region
    • 4.6.1. By Generalized seizures.
    • 4.6.2. By Focal seizures.
    • 4.6.3. By Patients treated with medications.
    • 4.6.4. By Patients treated with surgery.
    • 4.6.5. By Patients treated with other methods (brain and nerve stimulators, Ketogenic diet, etc.)
  • 4.7. Number of Clinics in each Country/Region with highlighted Leading Centers.
  • 4.8. Value Chain Analysis
  • 4.9. PESTLE Analysis
  • 4.10. Key Promotional Strategies

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. GDP Growth
    • 5.2.2. Strategic Developments by Key Players
    • 5.2.3. Technological Advancements
    • 5.2.4. Top Companies Historical Growth
    • 5.2.5. Research and Development funding
    • 5.2.6. Adoption of Epilepsy Treatment in Healthcare facilities
    • 5.2.7. Cost of Products
    • 5.2.8. Research collaboration
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Diagnosis & Treatment Type
    • 6.1.2. Revenue By Seizure Types
    • 6.1.3. By Distribution Channel
    • 6.1.4. Revenue By Service Provider
    • 6.1.5. Revenue By Region
  • 6.2. 2022 Market Scenario

7. Global Market Demand (in Value US$ Mn) Analysis 2019-2024 and Forecast, 2025-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Diagnosis & Treatment Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Diagnosis & Treatment Type, 2019-2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Diagnosis & Treatment Type, 2025-2032
    • 8.3.1. By Diagnosis
      • 8.3.1.1. Inpatient
      • 8.3.1.2. Outpatient
    • 8.3.2. By Treatment Type
      • 8.3.2.1. Drug Treatment
        • 8.3.2.1.1. Lamotrigine
        • 8.3.2.1.2. Phenytoin
        • 8.3.2.1.3. Carbamazepine
        • 8.3.2.1.4. Valproic Acid
        • 8.3.2.1.5. Others
      • 8.3.2.2. Surgery Treatment
      • 8.3.2.3. Other Treatment
    • 8.3.3. By Devices
      • 8.3.3.1. Monitoring device
        • 8.3.3.1.1. Electrocorticography (ECoG) Electrodes
        • 8.3.3.1.2. Intraoperative Patient Monitoring Devices
      • 8.3.3.2. Neurostimulation device
        • 8.3.3.2.1. Responsive Neurostimulation
        • 8.3.3.2.2. Deep Brain Stimulation
        • 8.3.3.2.3. Vagus Nerve Stimulation
  • 8.4. Market Attractiveness Analysis By Diagnosis & Treatment Type

9. Global Market Analysis 2019-2024 and Forecast 2025-2032 By Seizures Types

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Seizures Type, 2019-2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Seizures Type, 2025-2032
    • 9.3.1. Generalized Seizures
    • 9.3.2. Focal Seizures
    • 9.3.3. Both
  • 9.4. Market Attractiveness Analysis By Seizures Type

10. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025-2032
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Drug Stores
    • 10.3.4. Online Pharmacies
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Service Provider

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Service Provider, 2019-2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Service Provider, 2025-2032
    • 11.3.1. Hospitals
    • 11.3.2. Ambulatory Surgical Centers
    • 11.3.3. Diagnostic Centers
    • 11.3.4. Speciality Clinics
  • 11.4. Market Attractiveness Analysis By Service Provider

12. Global Market Analysis 2019-2024 and Forecast 2025-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2025-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East & Africa(MEA)
  • 12.4. Market Attractiveness Analysis by Region

13. North America Market Analysis 2019-2024 and Forecast 2025-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Diagnosis & Treatment Type
    • 13.3.3. By Seizures Type
    • 13.3.4. By Distribution Channel
    • 13.3.5. By Service Provider
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Diagnosis & Treatment Type
    • 13.4.3. By Seizures Type
    • 13.4.4. By Distribution Channel
    • 13.4.5. By Service Provider
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Diagnosis & Treatment Type
        • 13.8.1.2.2. By Seizures Type
        • 13.8.1.2.3. By Distribution Channel
        • 13.8.1.2.4. By Service Provider
    • 13.8.2. Canada Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Diagnosis & Treatment Type
        • 13.8.2.2.2. By Seizures Type
        • 13.8.2.2.3. By Distribution Channel
        • 13.8.2.2.4. By End-User

14. Latin America Market Analysis 2019-2024 and Forecast 2025-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Diagnosis & Treatment Type
    • 14.3.3. By Seizures Type
    • 14.3.4. By Distribution Channel
    • 14.3.5. By Service Provider
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Diagnosis & Treatment Type
    • 14.4.3. By Seizures Type
    • 14.4.4. By Distribution Channel
    • 14.4.5. By Service Provider
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Diagnosis & Treatment Type
        • 14.8.1.2.2. By Seizures Type
        • 14.8.1.2.3. By Distribution Channel
        • 14.8.1.2.4. By Service Provider
    • 14.8.2. Mexico Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Diagnosis & Treatment Type
        • 14.8.2.2.2. By Seizures Type
        • 14.8.2.2.3. By Distribution Channel
        • 14.8.2.2.4. By Service Provider
    • 14.8.3. Argentina Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Diagnosis & Treatment Type
        • 14.8.3.2.2. By Seizures Type
        • 14.8.3.2.3. By Distribution Channel
        • 14.8.3.2.4. By Service Provider

15. Europe Market Analysis 2019-2024 and Forecast 2025-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. Russia
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Diagnosis & Treatment Type
    • 15.3.3. By Seizures Type
    • 15.3.4. By Distribution Channel
    • 15.3.5. By Service Provider
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Diagnosis & Treatment Type
    • 15.4.3. By Seizures Type
    • 15.4.4. By Distribution Channel
    • 15.4.5. By Service Provider
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Diagnosis & Treatment Type
        • 15.8.1.2.2. By Seizures Type
        • 15.8.1.2.3. By Distribution Channel
        • 15.8.1.2.4. By Service Provider
    • 15.8.2. Italy Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Diagnosis & Treatment Type
        • 15.8.2.2.2. By Seizures Type
        • 15.8.2.2.3. By Distribution Channel
        • 15.8.2.2.4. By Service Provider
    • 15.8.3. France Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Diagnosis & Treatment Type
        • 15.8.3.2.2. By Seizures Type
        • 15.8.3.2.3. By Distribution Channel
        • 15.8.3.2.4. By Service Provider
    • 15.8.4. U.K. Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Diagnosis & Treatment Type
        • 15.8.4.2.2. By Seizures Type
        • 15.8.4.2.3. By Service Provider
    • 15.8.5. Spain Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Diagnosis & Treatment Type
        • 15.8.5.2.2. By Seizures Type
        • 15.8.5.2.3. By Distribution Channel
        • 15.8.5.2.4. By Service Provider
    • 15.8.6. BENELUX Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Diagnosis & Treatment Type
        • 15.8.6.2.2. By Seizures Type
        • 15.8.6.2.3. By Distribution Channel
        • 15.8.6.2.4. By Service Provider
    • 15.8.7. Nordic Countries Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Diagnosis & Treatment Type
        • 15.8.7.2.2. By Seizures Type
        • 15.8.7.2.3. By Distribution Channel
        • 15.8.7.2.4. By Service Provider
    • 15.8.8. Russia Market
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Diagnosis & Treatment Type
        • 15.8.8.2.2. By Seizures Type
        • 15.8.8.2.3. By Distribution Channel
        • 15.8.8.2.4. By Service Provider

16. South Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Philippines
      • 16.3.1.6. Vietnam
      • 16.3.1.7. Rest of South Asia
    • 16.3.2. By Diagnosis & Treatment Type
    • 16.3.3. By Seizures Type
    • 16.3.4. By Distribution Channel
    • 16.3.5. By Service Provider
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Diagnosis & Treatment Type
    • 16.4.3. By Seizures Type
    • 16.4.4. By Distribution Channel
    • 16.4.5. By Service Provider
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Diagnosis & Treatment Type
        • 16.8.1.2.2. By Seizures Type
        • 16.8.1.2.3. By Distribution Channel
        • 16.8.1.2.4. By Service Provider
    • 16.8.2. Thailand Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Diagnosis & Treatment Type
        • 16.8.2.2.2. By Seizures Type
        • 16.8.2.2.3. By Distribution Channel
        • 16.8.2.2.4. By Service Provider
    • 16.8.3. Indonesia Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Diagnosis & Treatment Type
        • 16.8.3.2.2. By Seizures Type
        • 16.8.3.2.3. By Distribution Channel
        • 16.8.3.2.4. By Service Provider
    • 16.8.4. Malaysia Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Diagnosis & Treatment Type
        • 16.8.4.2.2. By Seizures Type
        • 16.8.4.2.3. By Distribution Channel
        • 16.8.4.2.4. By Service Provider
    • 16.8.5. Philippines Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Diagnosis & Treatment Type
        • 16.8.5.2.2. By Seizures Type
        • 16.8.5.2.3. By Distribution Channel
        • 16.8.5.2.4. By Service Provider
    • 16.8.6. Vietnam Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Diagnosis & Treatment Type
        • 16.8.6.2.2. By Seizures Type
        • 16.8.6.2.3. By Distribution Channel
        • 16.8.6.2.4. By Service Provider

17. East Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Diagnosis & Treatment Type
    • 17.3.3. By Seizures Type
    • 17.3.4. By Distribution Channel
    • 17.3.5. By Service Provider
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Diagnosis & Treatment Type
    • 17.4.3. By Seizures Type
    • 17.4.4. By Distribution Channel
    • 17.4.5. By Service Provider
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Diagnosis & Treatment Type
        • 17.8.1.2.2. By Seizures Type
        • 17.8.1.2.3. By Distribution Channel
        • 17.8.1.2.4. By Service Provider
    • 17.8.2. Japan Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Diagnosis & Treatment Type
        • 17.8.2.2.2. By Seizures Type
        • 17.8.2.2.3. By Distribution Channel
        • 17.8.2.2.4. By Service Provider
    • 17.8.3. South Korea Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Diagnosis & Treatment Type
        • 17.8.3.2.2. By Seizures Type
        • 17.8.3.2.3. By Distribution Channel
        • 17.8.3.2.4. By Service Provider

18. Oceania Market Analysis 2019-2024 and Forecast 2025-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Diagnosis & Treatment Type
    • 18.3.3. By Seizures Type
    • 18.3.4. By Distribution Channel
    • 18.3.5. By Service Provider
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Diagnosis & Treatment Type
    • 18.4.3. By Seizures Type
    • 18.4.4. By Distribution Channel
    • 18.4.5. By Service Provider
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Diagnosis & Treatment Type
        • 18.8.1.2.2. By Seizures Type
        • 18.8.1.2.3. By Distribution Channel
        • 18.8.1.2.4. By Service Provider
    • 18.8.2. New Zealand Market
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Diagnosis & Treatment Type
        • 18.8.2.2.2. By Seizures Type
        • 18.8.2.2.3. By Distribution Channel
        • 18.8.2.2.4. By Service Provider

19. Middle East & Africa Market Analysis 2019-2024 and Forecast 2025-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of MEA
    • 19.3.2. By Diagnosis & Treatment Type
    • 19.3.3. By Seizures Type
    • 19.3.4. By Distribution Channel
    • 19.3.5. By Service Provider
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Diagnosis & Treatment Type
    • 19.4.3. By Seizures Type
    • 19.4.4. By Distribution Channel
    • 19.4.5. By Service Provider
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Diagnosis & Treatment Type
        • 19.8.1.2.2. By Seizures Type
        • 19.8.1.2.3. By Distribution Channel
        • 19.8.1.2.4. By Service Provider
    • 19.8.2. Turkiye Market
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Diagnosis & Treatment Type
        • 19.8.2.2.2. By Seizures Type
        • 19.8.2.2.3. By Distribution Channel
        • 19.8.2.2.4. By Service Provider
    • 19.8.3. South Africa Market
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Diagnosis & Treatment Type
        • 19.8.3.2.2. By Seizures Type
        • 19.8.3.2.3. By Distribution Channel
        • 19.8.3.2.4. By Service Provider
    • 19.8.4. North Africa Market
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Diagnosis & Treatment Type
        • 19.8.4.2.2. By Seizures Type
        • 19.8.4.2.3. By Distribution Channel
        • 19.8.4.2.4. By Service Provider

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Branding and Promotional Strategies
  • 21.3. Key Development Analysis
  • 21.4. Competition Deep Dive
    • 21.4.1. Medtronic Plc.
      • 21.4.1.1. Overview
      • 21.4.1.2. Key Financial
      • 21.4.1.3. Sales Footprint
      • 21.4.1.4. SWOT Analysis
      • 21.4.1.5. Key Developments
      • 21.4.1.6. Strategy Overview
        • 21.4.1.6.1. Marketing Strategy
        • 21.4.1.6.2. Product Strategy
        • 21.4.1.6.3. Channel Strategy
    • 21.4.2. GlaxoSmithKline
      • 21.4.2.1. Overview
      • 21.4.2.2. Key Financial
      • 21.4.2.3. Sales Footprint
      • 21.4.2.4. SWOT Analysis
      • 21.4.2.5. Key Developments
      • 21.4.2.6. Strategy Overview
        • 21.4.2.6.1. Marketing Strategy
        • 21.4.2.6.2. Product Strategy
        • 21.4.2.6.3. Channel Strategy
    • 21.4.3. Sun Pharmaceutical Industries Ltd
      • 21.4.3.1. Overview
      • 21.4.3.2. Key Financial
      • 21.4.3.3. Sales Footprint
      • 21.4.3.4. SWOT Analysis
      • 21.4.3.5. Key Developments
      • 21.4.3.6. Strategy Overview
        • 21.4.3.6.1. Marketing Strategy
        • 21.4.3.6.2. Product Strategy
        • 21.4.3.6.3. Channel Strategy
    • 21.4.4. Novartis India Ltd
      • 21.4.4.1. Overview
      • 21.4.4.2. Key Financial
      • 21.4.4.3. Sales Footprint
      • 21.4.4.4. SWOT Analysis
      • 21.4.4.5. Key Developments
      • 21.4.4.6. Strategy Overview
        • 21.4.4.6.1. Marketing Strategy
        • 21.4.4.6.2. Product Strategy
        • 21.4.4.6.3. Channel Strategy
    • 21.4.5. Teva Pharma Ltd
      • 21.4.5.1. Overview
      • 21.4.5.2. Key Financial
      • 21.4.5.3. Sales Footprint
      • 21.4.5.4. SWOT Analysis
      • 21.4.5.5. Key Developments
      • 21.4.5.6. Strategy Overview
        • 21.4.5.6.1. Marketing Strategy
        • 21.4.5.6.2. Product Strategy
        • 21.4.5.6.3. Channel Strategy
    • 21.4.6. Zydus Cadila Healthcare Ltd.
      • 21.4.6.1. Overview
      • 21.4.6.2. Key Financial
      • 21.4.6.3. Sales Footprint
      • 21.4.6.4. SWOT Analysis
      • 21.4.6.5. Key Developments
      • 21.4.6.6. Strategy Overview
        • 21.4.6.6.1. Marketing Strategy
        • 21.4.6.6.2. Product Strategy
        • 21.4.6.6.3. Channel Strategy
    • 21.4.7. Boston Scientific Corporation
      • 21.4.7.1. Overview
      • 21.4.7.2. Key Financial
      • 21.4.7.3. Sales Footprint
      • 21.4.7.4. SWOT Analysis
      • 21.4.7.5. Key Developments
      • 21.4.7.6. Strategy Overview
        • 21.4.7.6.1. Marketing Strategy
        • 21.4.7.6.2. Product Strategy
        • 21.4.7.6.3. Channel Strategy
    • 21.4.8. ElectroCore, Inc.
      • 21.4.8.1. Overview
      • 21.4.8.2. Key Financial
      • 21.4.8.3. Sales Footprint
      • 21.4.8.4. SWOT Analysis
      • 21.4.8.5. Key Developments
      • 21.4.8.6. Strategy Overview
        • 21.4.8.6.1. Marketing Strategy
        • 21.4.8.6.2. Product Strategy
        • 21.4.8.6.3. Channel Strategy
    • 21.4.9. LivaNova PLC
      • 21.4.9.1. Overview
      • 21.4.9.2. Key Financial
      • 21.4.9.3. Sales Footprint
      • 21.4.9.4. SWOT Analysis
      • 21.4.9.5. Key Developments
      • 21.4.9.6. Strategy Overview
        • 21.4.9.6.1. Marketing Strategy
        • 21.4.9.6.2. Product Strategy
        • 21.4.9.6.3. Channel Strategy
    • 21.4.10. NIHON KOHDEN CORPORATION
      • 21.4.10.1. Overview
      • 21.4.10.2. Key Financial
      • 21.4.10.3. Sales Footprint
      • 21.4.10.4. SWOT Analysis
      • 21.4.10.5. Key Developments
      • 21.4.10.6. Strategy Overview
        • 21.4.10.6.1. Marketing Strategy
        • 21.4.10.6.2. Product Strategy
        • 21.4.10.6.3. Channel Strategy
    • 21.4.11. Natus Medical Incorporated
      • 21.4.11.1. Overview
      • 21.4.11.2. Key Financial
      • 21.4.11.3. Sales Footprint
      • 21.4.11.4. SWOT Analysis
      • 21.4.11.5. Key Developments
      • 21.4.11.6. Strategy Overview
        • 21.4.11.6.1. Marketing Strategy
        • 21.4.11.6.2. Product Strategy
        • 21.4.11.6.3. Channel Strategy
    • 21.4.12. Neuro Soft
      • 21.4.12.1. Overview
      • 21.4.12.2. Key Financial
      • 21.4.12.3. Sales Footprint
      • 21.4.12.4. SWOT Analysis
      • 21.4.12.5. Key Developments
      • 21.4.12.6. Strategy Overview
        • 21.4.12.6.1. Marketing Strategy
        • 21.4.12.6.2. Product Strategy
        • 21.4.12.6.3. Channel Strategy
    • 21.4.13. Pfizer Inc.
      • 21.4.13.1. Overview
      • 21.4.13.2. Key Financial
      • 21.4.13.3. Sales Footprint
      • 21.4.13.4. SWOT Analysis
      • 21.4.13.5. Key Developments
      • 21.4.13.6. Strategy Overview
        • 21.4.13.6.1. Marketing Strategy
        • 21.4.13.6.2. Product Strategy
        • 21.4.13.6.3. Channel Strategy
    • 21.4.14. Abbott Laboratories
      • 21.4.14.1. Overview
      • 21.4.14.2. Key Financial
      • 21.4.14.3. Sales Footprint
      • 21.4.14.4. SWOT Analysis
      • 21.4.14.5. Key Developments
      • 21.4.14.6. Strategy Overview
        • 21.4.14.6.1. Marketing Strategy
        • 21.4.14.6.2. Product Strategy
        • 21.4.14.6.3. Channel Strategy
    • 21.4.15. Sanofi S.A.
      • 21.4.15.1. Overview
      • 21.4.15.2. Key Financial
      • 21.4.15.3. Sales Footprint
      • 21.4.15.4. SWOT Analysis
      • 21.4.15.5. Key Developments
      • 21.4.15.6. Strategy Overview
        • 21.4.15.6.1. Marketing Strategy
        • 21.4.15.6.2. Product Strategy
        • 21.4.15.6.3. Channel Strategy
    • 21.4.16. Cipla Ltd.
      • 21.4.16.1. Overview
      • 21.4.16.2. Key Financial
      • 21.4.16.3. Sales Footprint
      • 21.4.16.4. SWOT Analysis
      • 21.4.16.5. Key Developments
      • 21.4.16.6. Strategy Overview
        • 21.4.16.6.1. Marketing Strategy
        • 21.4.16.6.2. Product Strategy
        • 21.4.16.6.3. Channel Strategy
    • 21.4.17. Torrent Pharmaceuticals Ltd
      • 21.4.17.1. Overview
      • 21.4.17.2. Key Financial
      • 21.4.17.3. Sales Footprint
      • 21.4.17.4. SWOT Analysis
      • 21.4.17.5. Key Developments
      • 21.4.17.6. Strategy Overview
        • 21.4.17.6.1. Marketing Strategy
        • 21.4.17.6.2. Product Strategy
        • 21.4.17.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology